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Bacterial Dsb proteins catalyse the in vivo formation of disulfide bonds, a critical
step in the stability and activity of many proteins. Most studies on Dsb proteins
have focused on Gram-negative bacteria and thus the process of oxidative
folding in Gram-positive bacteria is poorly understood. To help elucidate this
process in Gram-positive bacteria, DsbA from Staphylococcus aureus (SaDsbA)
has been focused on. Here, the expression, purification, crystallization and
preliminary diffraction analysis of SaDsbA are reported. SaDsbA crystals
diffract to a resolution limit of 2.1 A˚ and belong to the hexagonal space group
P65 or P61, with unit-cell parameters a = b = 72.1, c= 92.1 A˚ and one molecule in
the asymmetric unit (64% solvent content).
1. Introduction
Disulfide bonds play a key role in the folding pathway of many
proteins and cells have evolved complex machineries to promote
disulfide catalysis. In the periplasmic space of Gram-negative
bacteria, the disulfide-bond (Dsb) proteins regulate the formation
and rearrangement of disulfide bonds during protein folding
(Kadokura et al., 2003; Masip et al., 2004). Escherichia coli Dsb
proteins form two pathways, the DsbA-DsbB pathway (Bardwell et
al., 1991, 1993), which rapidly introduces disulfide bonds into target
proteins, and the DsbC/DsbG-DsbD pathway (Rietsch et al., 1996),
which catalyses the rearrangement of incorrect disulfide bonds.
Protein disulfide catalysis has been studied extensively in E. coli,
but little information is available about this process in other organ-
isms. For example, Gram-positive bacteria do not have a classic
periplasmic compartment, but do contain an extraprotoplasmic
compartment confined between the plasma membrane and the outer
cell wall (Pooley et al., 1996; Matias & Beveridge, 2006), and genomic
sequence data indicates that they encode Dsb orthologues (Kouwen
et al., 2007). Moreover, functional Dsb homologues have been
described in Gram-positive organisms, including Bacillus brevis
(Ishihara et al., 1995), B. subtilis (Erlendsson & Hederstedt, 2002;
Dorenbos et al., 2002; Sarvas et al., 2004; Meima et al., 2002; Stein,
2005) and Mycobacterium tuberculosis (Goulding et al., 2004).
However, the mechanisms of disulfide catalysis in Gram-positive
bacteria remain mostly uncharacterized.
To investigate the oxidative folding of secreted proteins in Gram-
positive bacteria, we focused on Staphylococcus aureus, a human
pathogen that secretes disulfide-bond-containing virulence factors
(Dziewanowska et al., 1996). This organism encodes a DsbA homo-
logue (SaDsbA), a 23 kDa lipoprotein that shares just 15% sequence
identity with E. coli DsbA yet can functionally complement this
protein (Dumoulin et al., 2005). Here, we report the crystallization of
SaDsbA, which to the best of our knowledge is the first Gram-
positive DsbA to be crystallized.
2. Material and methods
2.1. Cloning, expression and protein purification
To prepare SaDsbA (AAG41993) for crystallization, a gene frag-
ment encoding a soluble form of the protein (residues 6–181 of the
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mature protein; Dumoulin et al., 2005) was cloned into a pET21a
vector (Novagen) using NheI and XhoI restriction sites. The cloning
procedure introduced four additional residues: two at the N-terminus
(Met-Ala) and two at the C-terminus (Leu-Glu). SaDsbA engineered
with a C-terminal hexahistidine tag was expressed in BL21 (DE3)
pLysS cells using autoinduction (Studier, 2005). Briefly, cells
harbouring pET21a-SaDsbA were grown with agitation at
200 rev min1 for 24 h at 303 K in minimal medium (Studier, 2005)
supplemented with 100 mg ml1 ampicillin.
The cells were then harvested by centrifugation and lysed in
50 mM Tris pH 7, 150 mM NaCl, 0.5% Triton-X, EDTA-free
protease-inhibitor cocktail (Roche) and DNase. Cell debris was
removed by centrifugation at 21 000g for 30 min. Histidine-tagged
SaDsbA was purified using cobalt-chelate chromatography (BD
TALON resin) and eluted with 50 mM Tris pH 7, 150 mM NaCl,
250 mM imidazole.
SaDsbA was oxidized by the addition of 1.7 mM copper(II)
1,10-phenanthroline (1 h, 277 K) and then equilibrated in 25 mM
4-(2-hydroxyethyl)-1-piperazine-N-2-ethanesulfonic acid (HEPES)
pH 6.7, 150 mM NaCl using a PD-10 column (GE Healthcare). The
protein was further purified by gel-filtration chromatography
(A¨KTA, GE Healthcare, Piscataway, NJ, USA) using a Superdex
S-200 column (GE Healthcare, Piscataway, NJ, USA) followed by
ion-exchange chromatography on a Mono S 5/50GL column (GE
Healthcare, Piscataway, NJ, USA).
Fractions containing SaDsbA were pooled and concentrated to
50 mg ml1 in 20 mM HEPES buffer pH 6.7, 50 mM NaCl using
Amicon Ultra centrifugal filter devices with 10 kDa cutoff (Millipore,
Billerica, MA, USA). The protein concentration was measured at
280 nm (NanoDrop ND-1000, NanoDrop Technologies, Wilmington,
DE, USA) and the purity was assessed by SDS–PAGE analysis and
mass spectrometry.
LC/MS analysis of SaDsbA was undertaken using an Applied
Biosystems/MDS SCIEX QSTAR Pulsar electrospray ionization
quadrupole time-of-flight (ESI QqTOF) mass spectrometer equipped
with an electrospray ionization source and linked to an upstream
Agilent 1100 Series HPLC system.
Selenomethionine (SeMet) SaDsbA was produced using pre-
viously described methods (Heras et al., 2003). Briefly, BL21(DE3)
pLysS cells harbouring pET21a-SaDsbA plasmid were grown at
310 K in M63 minimal medium containing 50 mg ml1 dl-seleno-
methionine. Cultures were induced with 0.5 mM IPTG (final
concentration) and harvested 3 h post-induction. SeMet SaDsbAwas
extracted and purified as described above for native SaDsbA.
2.2. Crystallization and diffraction data measurement
Initial crystallization trials were carried out using the sitting-drop
vapour-diffusion method in 96-well plates (Greiner low profile with
one and three drops per well) and commercial crystallization screens
including Crystal Screens I and II, PEG/Ion Screen, Sodium Malo-
nate Grid Screen (Hampton Research, San Diego, CA, USA), JB
Screen 2, JB Screen 3, Precipitant Synergy Screen andWizard I and II
(Jena Bioscience, Jena, Germany). The sitting-drop crystallization
trials were set up manually using a multi-channel pipette (Matrix
Impact, Thermo Fisher Scientific, Waltham, MA, USA); 1 ml protein
solution (50 mg ml1 in 25 mM HEPES pH 6.7, 50 mM NaCl) and
1 ml precipitant solution were added together and then equilibrated
against well solution (100 ml) in a temperature-controlled room at
293 K. The sitting-drop crystallization trials (800) failed to produce
crystals. Further trials were carried out using a TOPAZ FID Crys-
tallizer (TOPAZ Screening Chip 1.96) and OptiMix-1 and OptiMix-2
screens (Fluidigm Corporation, San Francisco, CA, USA). This
system requires just 1 ml of protein to screen 96 conditions. Using this
free-interface diffusion approach, crystals were observed in a
condition containing only 25% polyethylene glycol of average
molecular weight 3350 Da (PEG 3350). This condition was translated
following the manufacturer’s recommended procedure to 24-well
hanging-drop vapour-diffusion experiments using VDXm plates and
18 mm siliconized cover slips (Hampton Research, San Diego, CA,
USA). Higher concentrations of PEG 3350 were screened (25–35%
PEG 3350 in water) and three different protein:precipitant ratios
(1 ml:1 ml, 0.75 ml:1.25 ml and 0.5 ml:1.5 ml). The protein concentration
used in the optimization screens was 50 mg ml1 in 25 mM HEPES
pH 6.7, 50 mM NaCl. Crystals of SeMet SaDsbA were grown essen-
tially as described for the native protein.
2.3. X-ray diffraction
Diffraction data for native SaDsbA crystals were measured using a
Rigaku FR-E copper rotating-anode generator operated at 45 kVand
45 mA with Osmic Confocal Max-Flux optics (either HiRes2 or
Maxscreen; Rigaku Americas, Houston, TX, USA). Reflections were
measured with an R-AXIS IV++ imaging-plate area detector (Rigaku
Americas, Houston, TX, USA). A Cryo Industries CryoCool LN2
(Cryo Industries, Manchester, NH, USA) was used to cool the crys-
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Figure 1
Crystals of SaDsbA obtained in 30% PEG 3350 using the hanging-drop vapour-
diffusion method. The crystals reached typical dimensions of 0.2  0.15  0.6 mm.
The scale bar corresponds to 0.1 mm.
Table 1
Summary of X-ray data-measurement and processing statistics.
Values in parentheses are for the highest resolution shell.
Native SaDsbA SeMet SaDsbA
Wavelength (A˚) 1.5418 2.2909
Temperature (K) 100 100
Space group P65 or P61 P65 or P61
Unit-cell parameters (A˚, ) a = b = 72.1, c = 92.1,
 =  = 90,  = 120
a = b = 72.0, c = 92.4,
 =  = 90,  = 120
Solvent content (%) 64 64
Resolution range 50.0–2.1 (2.18–2.10) 50.0–2.44 (2.53–2.44)
No. of observations 176568 130808
No. of unique reflections 15961 (1578) 10161 (947)
Redundancy 11.1 (10.8) 12.9 (10.4)
Completeness (%) 100 (100) 99.5 (94.5)
Rmerge† 0.051 (0.236) 0.081 (0.407)
I/(I) 44.6 (15.1) 31.3 (5.6)
† Rmerge =
P jI  hIijPhIi, where I is the intensity of each individual reflection.
tals during data measurement. Diffraction data for SeMet SaDsbA
crystals were measured using X-rays from an RU-H2R-Cr generator
with chromium Osmic MaxFlux optics and R-AXIS IV++ detector
(Rigaku Americas, Houston, TX, USA). The crystal-to-detector
distance was 150 mm (SaDsbA) or 102 mm (SeMet SaDsbA). Crys-
tals were cryoprotected by soaking for 5 min in 30% PEG 3350 and
data were processed using HKL-2000 (Otwinowski & Minor, 1997).
3. Results and discussion
A standard vapour-diffusion approach using several commercial
crystallization screens failed to generate SaDsbA crystals. However,
using a free-interface diffusion crystallization chip we were able to
grow small elongated rod-shaped crystals in condition No. 54 of the
OptiMix-1 screen, which contains only 25% PEG 3350. This condition
was successfully translated to 24-well hanging-drop vapour-diffusion
experiments by screening higher concentrations of PEG 3350 and a
range of protein:precipitant ratios. Single hexagonal rod-shaped
crystals were obtained in 28–30% PEG 3350 in drops that had a
protein-to-precipitant ratio of less than 1 (Fig. 1). We observed that
crystals grown from freshly produced protein took twice as long to
grow (10 d) than crystals obtained from protein stored for a few
days at 277 K. Mass-spectrometric analysis of dissolved crystals
indicated that the protein in the crystals corresponded to a degra-
dation product in which the N-terminal four residues (MASA) and
C-terminal seven residues (KLEHHHHHH) were removed. Fortui-
tously, most of these residues corresponded to non-native residues
engineered into the construct.
These SaDsbA crystals diffract to 2.1 A˚ resolution on the high-
brilliance FR-E generator (Fig. 2). They belong to the hexagonal
space group P65 or P61, with unit-cell parameters a = b = 72.1,
c = 92.1 A˚,  =  = 90,  = 120. Assuming the crystals have one
molecule per asymmetric unit, the Matthews coefficient (VM) is
3.5 A˚3 Da1 and the solvent content is 64% (Matthews, 1968); both
are within the usual range for protein crystals. Statistics for the
diffraction data are provided in Table 1.
Initial attempts to solve the structure by molecular replacement
using E. coli DsbA as a model (Martin et al., 1993) and either CNS
(Bru¨nger et al., 1998) or Phaser (Storoni et al., 2004) failed to produce
a solution (15% sequence identity). We therefore produced SeMet
SaDsbA crystals in order to attempt in-house SAD phasing using
Cr K radiation ( = 2.29 A˚). Measuring data at this wavelength
doubles the anomalous signal of many elements, including sulfur
(f 0 0 = 1.14 e) and selenium (f 0 0 = 2.28 e), compared with Cu K
radiation ( = 1.54 A˚; f 0 0 = 0.56 and 1.14 e for S and Se, respec-
tively). SeMet SaDsbA crystals diffracted to the corner of the
detector (2.44 A˚ resolution) on the RU-H2R generator, with unit-cell
parameters a = b = 72.0, c = 92.4 A˚,  =  = 90,  = 120 (Table 1).
However, the signal was weak for Se-SAD/Cr data (anomalous signal
d0 0/ at 3.5 A˚ of 0.98), so that the most likely route for phasing will be
MAD or SAD data measurement at a synchrotron.
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